Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
BMJ Case Reports
|
April 21, 2016
Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema
Mark M Hassall, Nicholas Howard Andrew
Clinical & Experimental Ophthalmology
|
June 2, 2018
Canaloplasty case series for primary open-angle glaucoma in rural Australia
Deric W De Wit, Mark M Hassall
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|
January 29, 2021
Ruptured Retinal Arterial Macroaneurysm
Liana Dedina, Mark M Hassall, Paula Anderson
The Yale Journal of Biology and Medicine
|
December 21, 2017
Gene Therapy for Color Blindness
Mark M Hassall, Alun R Barnard, Robert E MacLaren
Neuro-Ophthalmology (Aeolus Press)
|
March 11, 2022
Pallid Disc Oedema in a Young Patient: Clinical and Diagnostic Challenge
Liana Dedina, Mark M Hassall, Shilpanjali Jesudason, et al.
Ophthalmology
|
May 14, 2026
Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years: Long-term Follow-up from The 'Bevacizumab in Trabeculectomy Study'
John Landers, Sean Mullany, Mark M Hassall, et al.
Annual Review of Genomics and Human Genetics
|
April 10, 2024
Polygenic Risk Scores Driving Clinical Change in Glaucoma
Antonia Kolovos, Mark M Hassall, Owen M Siggs, et al.
BMC Medical Genomics
|
January 30, 2025
Development and evaluation of patient-centred polygenic risk score reports for glaucoma screening
Georgina L Hollitt, Mark M Hassall, Owen M Siggs, et al.
Ophthalmology
|
June 13, 2025
REPLY
Antonia Kolovos, Ayub Qassim, Mark M Hassall, et al.
Translational Vision Science & Technology
|
June 10, 2021
Risk Stratification and Clinical Utility of Polygenic Risk Scores in Ophthalmology
Ayub Qassim, Emmanuelle Souzeau, Georgie Hollitt, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
BMJ Case Reports
|
April 21, 2016
Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema
Mark M Hassall, Nicholas Howard Andrew
Clinical & Experimental Ophthalmology
|
June 2, 2018
Canaloplasty case series for primary open-angle glaucoma in rural Australia
Deric W De Wit, Mark M Hassall
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|
January 29, 2021
Ruptured Retinal Arterial Macroaneurysm
Liana Dedina, Mark M Hassall, Paula Anderson
The Yale Journal of Biology and Medicine
|
December 21, 2017
Gene Therapy for Color Blindness
Mark M Hassall, Alun R Barnard, Robert E MacLaren
Neuro-Ophthalmology (Aeolus Press)
|
March 11, 2022
Pallid Disc Oedema in a Young Patient: Clinical and Diagnostic Challenge
Liana Dedina, Mark M Hassall, Shilpanjali Jesudason, et al.
Ophthalmology
|
May 14, 2026
Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years: Long-term Follow-up from The 'Bevacizumab in Trabeculectomy Study'
John Landers, Sean Mullany, Mark M Hassall, et al.
Annual Review of Genomics and Human Genetics
|
April 10, 2024
Polygenic Risk Scores Driving Clinical Change in Glaucoma
Antonia Kolovos, Mark M Hassall, Owen M Siggs, et al.
BMC Medical Genomics
|
January 30, 2025
Development and evaluation of patient-centred polygenic risk score reports for glaucoma screening
Georgina L Hollitt, Mark M Hassall, Owen M Siggs, et al.
Ophthalmology
|
June 13, 2025
REPLY
Antonia Kolovos, Ayub Qassim, Mark M Hassall, et al.
Translational Vision Science & Technology
|
June 10, 2021
Risk Stratification and Clinical Utility of Polygenic Risk Scores in Ophthalmology
Ayub Qassim, Emmanuelle Souzeau, Georgie Hollitt, et al.
Page
of 3